Improved Glycemic Control with metformin Glibenclamide combined tablet therapy (Glucovance® ) in type 2 diabetic patients inadequately controlled on metformin
(2002) Diabetic Medicine: journal of diabetes UK — Vol. 19, p. 673-680 (2002)
Files
No attached file found for this publication.
Details
- Authors
Lehert, Philippe 
- Abstract
- (en) To evaluate efficacy and safety of two dosage strengths of a single-tablet metformin–glibenclamide (glyburide) combination, compared with the respective monotherapies, in patients with Type 2 diabetes mellitus (DM) inadequately controlled by metformin monotherapy. 16-week, double-blind, multicentre, parallel-group trial, 411 patients were randomized to receive metformin 500 mg, glibenclamide 5 mg, metformin–glibenclamide 500 mg/2.5 mg or metformin–glibenclamide 500 mg/5 mg. Decreases in glycated haemoglobin (HbA1c) and FPG were greater (P < 0.05) for metformin–glibenclamide 500 mg/2.5 mg (-1.20% and -2.62 mmol/l) and 500 mg/5 mg (-0.91% and -2.34 mmol/l), compared with metformin (-0.19% and -0.57 mmol/l) or glibenclamide (-0.33% and -0.73 mmol/l). These benefits were achieved at lower mean doses of metformin or glibenclamide with metformin–glibenclamide 500 mg/2.5 mg and 500 mg/5 mg (1225 mg/6.1 mg and 1170 mg/11.7 mg) than with glibenclamide (13.4 mg) or metformin (1660 mg).
- Affiliations
Louvain School of Management
Citations
Marre, M., Allavoine, Th., Lehert, P., & Howlett, H. (2002). Improved Glycemic Control with metformin Glibenclamide combined tablet therapy (Glucovance® ) in type 2 diabetic patients inadequately controlled on metformin. Diabetic Medicine: journal of diabetes UK, 19, 673-680. https://doi.org/10.1046/j.1464-5491.2002.00774.x (Original work published 2002)